Who are Dopaminergic Agonists's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Rasagiline mesylate with Requip, DEP-Ru, SPD503 (2 mg).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dopaminergic-agonists.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dopaminergic Agonists — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dopaminergic Agonists (Dopaminergic Agonists) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine receptor agonist. Area: Neurology.

marketed Dopamine receptor agonist Dopamine receptors (D1-D5) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Dopaminergic Agonists (Dopaminergic Agonists) — Sandoz. Dopaminergic agonists activate dopamine receptors in the brain to increase dopamine signaling.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dopaminergic Agonists TARGET	Dopaminergic Agonists	Sandoz	marketed	Dopamine receptor agonist	Dopamine receptors (D1-D5)
Rasagiline mesylate with Requip	Rasagiline mesylate with Requip	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine receptor agonist	MAO-B and dopamine D2/D3 receptors
DEP-Ru	DEP-Ru	Beijing Friendship Hospital	phase 3	Dopamine receptor agonist	Dopamine receptor
SPD503 (2 mg)	SPD503 (2 mg)	Shire	phase 3	dopamine receptor agonist	Dopamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine receptor agonist class)

Beijing Friendship Hospital · 1 drug in this class
Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dopaminergic Agonists — Competitive Intelligence Brief. https://druglandscape.com/ci/dopaminergic-agonists. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing